Kalaris Therapeutics, Inc.
KLRS
$3.08
$0.5220.31%
NASDAQ
06/30/2025 | 06/30/2024 | ||||
---|---|---|---|---|---|
Net Income | -11.32% | -65.84% | |||
Total Depreciation and Amortization | -- | -- | |||
Total Amortization of Deferred Charges | -100.00% | 69.10% | |||
Total Other Non-Cash Items | 165.02% | 201.78% | |||
Change in Net Operating Assets | -175.87% | 91.71% | |||
Cash from Operations | -68.51% | 12.17% | |||
Capital Expenditure | -- | -- | |||
Sale of Property, Plant, and Equipment | -- | -- | |||
Cash Acquisitions | -- | -- | |||
Divestitures | -- | -- | |||
Other Investing Activities | -- | -- | |||
Cash from Investing | -- | -- | |||
Total Debt Issued | -100.00% | 0.14% | |||
Total Debt Repaid | -- | -- | |||
Issuance of Common Stock | -- | -- | |||
Repurchase of Common Stock | -- | -- | |||
Issuance of Preferred Stock | -- | -100.00% | |||
Repurchase of Preferred Stock | -- | -- | |||
Total Dividends Paid | -- | -- | |||
Other Financing Activities | -100.00% | -240.00% | |||
Cash from Financing | -100.00% | -24.26% | |||
Foreign Exchange rate Adjustments | -- | -- | |||
Miscellaneous Cash Flow Adjustments | -- | -- | |||
Net Change in Cash | -112.56% | -50.83% | |||